Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Vice President, Finance (PAO) | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,258 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 2,925 · Balance 11,258 F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. F2: Includes restricted stock units. F3: The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Includes restricted stock units.
F3: The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 23:26 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 2,925 | $9.13 | $26,702.33 |
DisclosureSEC source: 0001193125-26-394734 · ownership.xml · nonDerivative · entry 1 Rueb Yuliya · CIK 0002125370 · Vice President, Finance (PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,258 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. F2 · balance_after: Includes restricted stock units. F3 · balance_after: The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $33.93 | $0.00 |
DisclosureSEC source: 0001193125-26-212111 · ownership.xml · derivative · entry 2 Rueb Yuliya · CIK 0002125370 · Vice President, Finance (PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-05-04 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-212111 · ownership.xml · nonDerivative · entry 1 Rueb Yuliya · CIK 0002125370 · Vice President, Finance (PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,354 F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.